All-trans retinoic acid is a potent promoter of cellular differentiation processes, which is used in cancer therapy. Glioblastoma spheroid cultures are enriched in tumorinitiating cells, and provide a model to test new treatment options in vitro. We investigated the molecular mechanisms of response to exposure to differentiation-promoting conditions in such cultures. Microarray analyses of five independent cultures showed that after induction of differentiation, inhibitors of transforming growth factorb/bone morphogenetic protein, Wnt/b-catenin and IGF signaling were upregulated, whereas expression of several microRNAs decreased, particularly that of the miR-17-92 cluster. In primary astrocytic gliomas (n ¼ 82), expression of several members of miR-17-92 was significantly higher relative to those of normal brain (n ¼ 8) and significantly increased with tumor grade progression (Po0.05). A high-level amplification of the miR-17-92 locus was detected in one glioblastoma specimen. Transfection of inhibitors of miR-17-92 induced increased apoptosis and decreased cell proliferation in glioblastoma spheroids. Mir-17-92 inhibition was also associated with increased messenger RNA (mRNA) and/or protein expression of CDKN1A, E2F1, PTEN and CTGF. The CTGF gene was shown to be a target of miR-17-92 in glioblastoma spheroids by luciferase reporter assays. Our results suggest that miR-17-92 and its target CTGF mediate effects of differentiation-promoting treatment on glioblastoma cells through multiple regulatory pathways.
Introduction
Glioblastoma (GBIV) is the most common primary brain tumor in adults. The median survival time after diagnosis for this highly malignant tumor has only improved marginally in the last decades and is still less than one year in population-based studies (Ohgaki and Kleihues, 2005) . Evidence from several groups has shown that GBIVs contain a rare, highly tumorigenic, self-renewing sub-population of cells, the so-called GBIV tumor-initiating cell population (Galli et al., 2004; Singh et al., 2004; Yuan et al., 2004) . Promotion of tumor-initiating cell differentiation may arise as a potential strategy for eradication of brain tumorinitiating cells (Piccirillo et al., 2006; Aguado et al., 2007) . All-trans retinoic acid (ATRA) is a differentiating agent that is effectively used to treat promyelocytic leukemia (Ohno et al., 2003) . In gliomas, ATRA was shown to induce differentiation accompanied by increased apoptosis and decreased proliferation of cell lines both in vitro and in xenograft experiments (Karmakar et al., 2007; Das et al., 2008; Lu et al., 2008) . Studies in our laboratories have shown that GBIV stem cell-enriched spheroid cultures become less tumorigenic, less invasive, less angiogenic and more sensitive to therapy after treatment with ATRA simultaneously to stem cell growth-factor removal and serum addition (Campos et al., submitted) .
The molecular mechanisms underlying ATRA treatment of GBIV spheroid cultures remain largely unknown. Recent gene-expression profiling analyses showed that serum factors, most likely bone morphogenetic protein 4, induce astrocyte differentiation of human normal neural progenitor cells by upregulating the expression of inhibitor of differentiation (ID) family genes (Obayashi et al., 2009) and that ATRA treatment of a glioblastoma cell line induces up-or downregulation of 42 genes, among which are the astrocytic lineage marker GFAP and the oncogene MDM2 (Zeng et al., 2009) .
In addition to the classic molecular signaling involving protein-coding genes, recent studies indicate that microRNAs (miRNAs) are essential regulators of cellular differentiation and proliferation, which have been implicated in the etiology of a number of cancers (Medina et al., 2008; Mendell, 2008; Gangaraju and Lin, 2009) . The role of miRNAs in brain tumorigenesis, however, remains poorly understood. miR-21 was shown to be highly expressed in GBIV compared with nonneoplastic brain and to function as an anti-apoptotic and pro-invasive factor (Chan et al., 2005; Corsten et al., 2007; Papagiannakopoulos et al., 2008) . miR-221 and miR-222 were shown to be highly expressed in GBIV relative to adjacent the normal brain tissue and to be involved in regulation of cell cycle checkpoints (Gillies and Lorimer, 2007; Medina et al., 2008; Conti et al., 2009) . The expression of miR-124, miR-137, miR-146b, miR-7, miR-181, miR-128 and miR-451 was found to be lower in GBIV compared with the non-neoplastic brain and inhibitors of glioma cell growth (Gal et al., 2008; Godlewski et al., 2008; Kefas et al., 2008; Shi et al., 2008; Silber et al., 2008; Xia et al., 2009) .
In this study, we investigated the molecular effects of exposure to differentiation-promoting conditions by characterizing treatment-related changes of messenger RNA (mRNA) and miRNA expression, and by performing functional analysis of the miR-17-92 cluster in GBIV spheroid cultures.
Results
Signaling pathways associated with self-renewal are inhibited on exposure to differentiation-promoting conditions To identify signaling pathways regulated upon exposure to differentiation-promoting conditions, we treated five GBIV spheroid cultures with ATRA simultaneously to growth factor removal and serum addition. We observed that this combination offered the most effective promotion of differentiation. Comparison of the gene expression profiles of the five cultures before and after induction identified 99 and 6 genes that were up-and downregulated (fold change 42), respectively. Among the most strongly upregulated genes, upon induction (Table 1) , were differentiation markers (for example, GFAP), a number of genes involved in ATRA signaling and metabolism (for example, RARB and CYP26B1), and inhibitors of signaling pathways associated with self-renewal and differentiation, such as transforming growth factor-b/bone morphogenetic protein signaling (for example, SMAD 6 and BAMBI), Wnt/b-catenin signaling (for example, SFRP4 and DKK3) and IGF signaling (for example, CYR61, IGFBP3, IGFBP5, CTGF, IGFBP6 and NOV). The top differentially regulated canonical pathways identified by pathway analysis were insulin-like growth factor 1 signaling (P ¼ 1.5 Â 10E5), vitamin D receptor/retinoic acid X receptor activation (P ¼ 1.33 Â 10E3), Wnt/b-catenin signaling (P ¼ 1.76 Â 10E2) and retinoic acid receptor activation (P ¼ 1.98 Â 10E2).
DNA de-methylation is observed at CpG sites associated with cancer-relevant genes To evaluate the potential regulatory role of epigenetic mechanisms in induction, we analysed the methylation status of CpG sites associated with a subset of 807 cancer-relevant genes and integrated the results with the gene expression data. DNA de-methylation (Po0.01) with concomitant upregulation was observed for CTGF, IGFBP6, SERPINE1, IGFBP3 and RARB (Supplementary Table 2 ).
Expression of the miR-17-92 cluster is downregulated upon induction of differentiation To gain further insight into the molecular mechanisms underlying exposure to differentiation-promoting conditions, we measured miRNA expression of the five GBIV spheroid cultures before and after induction using miRNA expression arrays. A total of 28 miRNAs were downregulated upon treatment and eight were upregulated (X1.6-fold; Table 2 ). Five miRNAs from the miR17-92 cluster and two from paralog clusters, miR106b-25 and miR-106a-363, were among the most strongly downregulated miRNAs (indicated in bold face). Paired t-tests showed that expression levels of all the members of miR-17-92, except for miR-92a-1, were significantly lower in induced cells compared with untreated cells.
miR-17-92 is amplified and overexpressed in glioblastomas
To investigate the possible oncogenic role of the miR-17-92 cluster in GBIV, we first examined its genomic status and expression level in clinical GBIV samples. miR-17-92 is located on chromosome band 13q31.3, a genomic region that is not amplified frequently in glioma. However, in a screen of 86 GBIVs (data not shown), we detected a high-level amplification of this locus in one primary GBIV by array comparative genomic hybridization ( Figure 1a ). We validated this amplification by fluorescence in situ hybridization (FISH) (Figure 1b ). In addition, FISH analysis of a tissue microarray containing 30 GBIVs randomly picked among the 86 GBIV samples identified three specimens (10%) exhibiting a gain of the 13q31.3 locus. To analyse the expression of the miR-17-92 cluster, we performed real-time stem-loop RT-PCR of miRNAs in primary human astrocytic glioma tissue specimens (n ¼ 82) and in non-neoplastic brain control tissues (n ¼ 8; Figure 2 ). Expression levels of miR-17-3p were significantly higher in primary GBIV relative to non-neoplastic brain. Expression levels of miR-17-3p, miR-17-5p, miR-92a-1 (Figure 2 ) and miR-106b (Supplementary Figure 2) were significantly higher in secondary GBIV relative to non-neoplastic brain. mir-19a and mir-19b were expressed at lower levels compared with the nonneoplastic brain. miR-17-5p, miR-19a and miR-106b showed a significantly higher expression in secondary GBIV specimens compared with astrocytoma grade II specimens.
Inhibition of the miR-17-92 cluster leads to decreased cell viability and decreased cell proliferation We next aimed to assess the functional significance of our findings using GBIV spheroid cultures. NCH421k cells were transfected with either anti-miR mix directed against all six miRNAs of the miR-17-92 cluster or control scrambled oligonucleotide. Cell proliferation, cell viability and apoptosis rates were assessed 72 h after transfection. On miR-17-92 inhibition, cell viability and cell proliferation were significantly reduced relative to cells transfected with scrambled control (Figures 3a and b) .
For apoptosis rate analysis, we quantified the percentages of early apoptotic cells that are annexin V-positive, but 7-amino-actinomycin-negative, and annexin V/7-amino-actinomycin-double-positive late apoptotic cells. Our results showed that inhibition of miR-17-92 induced a significant increase in apoptotic cells (Po0.05, Figure 3c ). Expression levels of astrocytic differentiation Gene identified as putative miRNA target according to prediction algorithms miRanda, TargetScan and Pictar. Only differentially expressed miRNAs upon induction were included in the analysis.
CTGF target of the miR-17-92 cluster in glioblastoma A Ernst et al marker glial fibrillary acidic protein and stem cell marker CD133 were not significantly changed on miR-17-92 inhibition (Supplementary Figure 3) .
miR-17-92 inhibits CDKN1A, E2F1 and PTEN expression in GBIV cells
To gain insight into the molecular mechanisms by which miR-17-92 exerts proliferative and anti-apoptotic effects in GBIV cells, we assessed the expression of CDKN1A, BCL2L11, PTEN and E2F1 after transfection of miR-17-92 inhibitors (Supplementary Figure 4) . These known regulators of the cell cycle and apoptosis had been identified as targets of miR-17-92 in other cell types. We observed a de-repression of CDKN1A and E2F1 at the mRNA level and of E2F1 and PTEN at the protein level in response to anti-miR transfection. The expression of BCL2L11 was altered neither at the mRNA nor at the protein level.
miR-17-92 targets CTGF in GBIV cells
To identify genes that might be of relevance in explaining the phenotypic effects of the exposure to differentiation-promoting conditions of GBIV cells, we performed an integrative analysis of the data. The CTGF gene was the only regulated gene upon induction (fold change 42) for which potential regulation by both DNA methylation and miRNA possibly occurred (Supplementary Tables 2 and 3 ). The CTGF gene is a predicted target of several members of the miR-17-92 cluster, namely miR18a, miR-19a and miR-19b (Table 1) . In our dataset, expression of miR-18a, miR19a and miR-19b was inversely correlated with mRNA expression of CTGF (Table 3 ). Separate analysis of the five GBIV cultures showed differences in induction response patterns (Figures 4a-d ). The CTGF gene was strongly upregulated upon treatment in three cultures, downregulated in the culture having the highest CTGF basal level, and remained unchanged in one culture that was less sensitive to treatment. To assess whether CTGF might be a target of miR-17-92, we measured CTGF mRNA expression on inhibition of miR-18a, which showed the strongest inverse correlation with CTGF (Table 3) . De-repression of the CTGF transcript was observed after anti-miR-18a transfection ( Figure 4e ). To validate that the 3 0 -untranslated region of CTGF is a direct target of miR-18a, we used a luciferase reporter system, in which the predicted miR-18a-binding site of CTGF was cloned downstream of a luciferase gene. Co-transfection of NCH421k cells with a CTGF 3 0 -untranslated region reporter and miR-18a resulted in a decrease in luminescence relative to cells co-transfected with a CTGF 3 0 -untranslated region reporter and empty vector (Figure 4f ). Therefore, miR-18a is targeting CTGF in GBIV cells, and downregulation of the oncogenic miR-17-92 cluster is directly related to the concomitant upregulation of CTGF on exposure to differentiationpromoting conditions.
Discussion
In this study, we investigated the effect of exposure to differentiation-promoting conditions on the expression profile of glioma stem cell-enriched spheroid cultures. We observed that the top canonical pathways inactivated in induced cells were insulin-like growth factor 1 signaling and Wnt/b-catenin signaling, both pathways being active in stem cells and regulating differentiation in the central nervous system (Malaterre et al., 2007; D'Ercole and Ye, 2008) . Consistent with our results, ATRA was shown to inhibit the growth of glioma cell lines partly by suppressing the activity of the Wnt/bcatenin signaling pathway by changing the subcellular localization of b-catenin (Lu et al., 2007) . Obayashi et al. (2009) performed gene-expression profiling of human non-neoplastic neural progenitor cells after serum-induced astrocyte differentiation. Interestingly, only 13 of the 45 more than two-fold upregulated genes (29%) that were identified in their study were among the 99 more than two-fold up-regulated genes in our data set. This relatively small overlap suggests that the majority of upregulated genes in our glioma spheroid cultures seem to be indeed induced by ATRA and not by factors present in the serum. The ATRA signaling and metabolism were also activated on treatment; for instance, retinoic acid receptor-b (RARB) and cytochrome P450, CYP26B1, an enzyme degrading retinoic acid, were upregulated in induced cells. We showed that the miR-17-92 cluster was downregulated upon induction of GBIV spheroid cultures and that inhibition of miR-17-92 lead to increased apoptosis rates. Recently, we showed that exposure to differentiation-promoting conditions induces anti-tumorigenic, anti-invasive and anti-angiogenic effects in vivo. We also showed that the percentage of apoptotic in differentiation processes. However, the miR-17 family was shown by others to regulate stem cell differentiation during mammalian development (Foshay and Gallicano, 2009 ).
miR-17-92 follows an oncofetal expression pattern: the expression of this cluster is high during embryonic development (Wienholds et al., 2005; Lu et al., 2007) , declines as development proceeds to remain low in most adult tissues, and re-expression occurs in many human cancers (Monzo et al., 2008; Navarro et al., 2009 ). In addition, overexpression of miR-17-92 promotes proliferation and inhibits differentiation of lung epithelial progenitor cells (Lu et al., 2007) .
Despite a well-established role in tumorigenesis, a function for miR-17-92 in adult tumors of the central nervous system had not been described to date. Widespread amplification and overexpression were reported in hematopoietic malignancies and tumors of the breast, colon, lung, pancreas and stomach (Mendell, 2008) . Transcriptional activation by the MYC and MYCN oncogenes has been reported and miRNAs from the miR-17-92 cluster were found overexpressed in aggressive neuroblastomas with MYCN amplification (Schulte et al., 2008) . A recent study in pediatric medulloblastoma showed recurrent amplifications of miR-17-92 in 6% of pediatric medulloblastomas (Northcott et al., 2009) ; components of the miR-17/92 cluster were also the most highly upregulated miRNAs in medulloblastoma (Uziel et al., 2009) . The authors further showed that miR-17-92 aberrant expression/amplification conferred a growth advantage to medulloblastomas.
In this study, DNA copy-number variation constitutes an infrequent mechanism underlying the activation of the miR-17-92 locus; other mechanisms probably explain the higher expression of components of the mir-17-92 cluster in GBIV compared with the non-neoplastic brain. We identified several components of the miR-17-92 cluster that showed a progression-dependent increase in expression from grade II to grade IV. These results are consistent with data from the study by Malzkorn et al. (2009) , who performed expression profiles of 157 miRNAs in four patients with WHO grade II astrocytic gliomas that spontaneously progressed to GBIVs. Three miRNAs from the miR-17-92 cluster, namely miR-17, miR-19a and miR-20a figured among the 12 miRNAs showing significantly increased expression upon tumor grade progression. Intriguingly, we found that miR-19a and miR-19b were expressed at significantly lower levels in GBIV compared with normal brain. However, overexpression of a subset of members of the cluster excluding miR-19a and miR-19b was previously reported . Such differences in the expression levels of individual members of the cluster may be explained by independent post-transcriptional regulation mechanisms. In line with this hypothesis, inconsistent expression of different miRNA members belonging to the same cluster was also reported in previous studies . As mir-19a and miR19b are expressed at low levels, the downregulation of these two miRNAs might, in contrast to other miRNAs of the cluster, not be as relevant to explain the phenotypic effects of the differentiation-promoting treatment.
Our results confirmed miR-17-92 targets that had been validated previously in other cell types, with the exception of BCL2L11 that was not targeted by miR-17-92 in our GBIV spheroid cultures and might represent a target specific to other cell types. Several studies begun to elucidate the molecular mechanisms by which miR-17-92 regulates proliferation and apoptosis. In vitro and in vivo treatment with antagomir-17-5p was shown to reduce the growth of MYCN-amplified and therapyresistant neuroblastoma through CDKN1A and BCL2L11 upregulation, leading to cell cycling blockade and activation of apoptosis, respectively (Fontana et al., 2008) . The CDKN1A gene was identified as an essential target of miR-17-92 during B-cell lymphomagenesis; transfection of antisense oligonucleotides against miR-17 and miR-20a into cell line, Jeko-1, led to upregulation of CDKN1A, resulting in decreased cell growth with G1-to-S arrest (Inomata et al., 2009) . The phosphatase and tensin homolog protein was reported as a target of miR-19a in HeLa cells (Lewis et al., 2003) and is a tumor suppressor protein frequently inactivated in GBIV. The E2F1 gene was also identified as a target of miR-17-5p and miR-20a in HeLa cells (O'Donnell et al., 2005) .
We showed that CTGF is a target of miR-17-92. In a different context, CTGF was independently identified as a target of miR-18a involved in endochondral ossification very recently (Ohgawara et al., 2009) . From our results, there seems to be an additional mechanism to regulate CTGF expression: upregulation of CTGF on treatment may partly be due to DNA de-methylation, as CTGF was one of the genes for which associated CpG sites showed the most significant differential methylation upon induction. Interestingly, connective tissue growth factor was shown to bind vascular endothelial growth factor (VEGFA), which is a central mediator of angiogenesis (Ferrara, 2002) , and to inhibit VEGFAinduced angiogenesis (Inoki et al., 2002) . In line with these results, levels of tumor cell-secreted VEGFA decreased up to 82% in conditioned medium of induced GBIV cells compared with untreated spheroids (Campos et al., submitted). Therefore, upregulation of CTGF on exposure to differentiation-promoting conditions might lead to inhibition of VEGFA-induced angiogenesis and explain partly the loss of angiogenic properties observed on induction. In addition, VEGFA was shown to induce upregulation of miR-17-92 (Sua´rez et al., 2008) . Decreased levels of secreted VEGFA detected upon induction might therefore explain to a certain extent the concomitant downregulation of the miR-17-92 cluster. In addition, miR-17-92 was shown to induce angiogenesis in solid tumors; Dews et al. (2006) showed in a mouse model that miR-17-92 transduced cells formed larger, better-perfused tumors.
In conclusion, the interaction between CTGF, VEG-FA and miR-17-92 might have a central role in GBIV pathogenesis. Furthermore, ATRA-based treatment might serve as a useful model to investigate for the development of therapeutic alternatives for GBIV by differentiation of malignant cells.
Materials and methods

Patient samples
Glioma samples, for analysis through TaqMan array miRNA panels and for array comparative genomic hybridization analysis, were selected from the collection of frozen brain tumor tissue specimens at the Department of Neuropathology, Heinrich-Heine University, Du¨sseldorf, and investigated in accordance with protocols approved by the institutional review board (study numbers 2767 and 2835).
Quantitative RT-PCR A total of 1 mg of total RNA was treated with DNaseI (Invitrogen, Karlsruhe, Germany) and reverse-transcribed with SuperscriptII (Invitrogen, Karlsruhe, Germany). Each complimentary DNA sample was analysed in triplicate with the ABI PRISM 7700 (Applied Biosystems, Foster City, CA, USA) using Absolute SYBR Green ROX Mix (ABgene, Epsom, UK) according to the manufacturer's instructions. Two endogenous housekeeping genes (ARF1 and DCTN2) were used as internal standards. All primers were tested to exclude amplification from genomic DNA. The relative quantification of the RNA of interest in comparison with the housekeeping genes was calculated according to a previously published algorithm (Pfaffl, 2001 TaqMan array miRNA panel Expression of 384 mature miRNAs was analysed by the TaqMan real-time PCR miRNA array (Applied Biosystems) under conditions defined by the supplier. Analyses were performed using the ABI PRISM 7700 (Applied Biosystems).
DNA methylation analysis
Array-based methylation analysis was carried out using the GoldenGate methylation cancer panel I (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. Briefly, bisulfite-converted DNA was hybridized to methylation-specific oligonucleotides and washed. The hybridized oligonucleotides were then extended and ligated to create templates for PCR amplification with fluorescently labeled primers. Amplification, labeling, hybridization and array images were provided by the DKFZ Genomics Core Facility. Data were analysed using the Beadstudio software (Illumina). The difference in methylation levels between untreated and induced cells was considered significant for Po0.01. For each CpG site, b-values are reported, which represent fractional methylation values ranging from 0 in the case of completely unmethylated CpG sites to 1 in the case of completely methylated sites. ''DiffScores'' are quantitative measures for the difference in methylation levels between sample groups: a DiffScore equal to 20, 30 or 40 corresponds to a significant P-value equal to 0.01, 0.001 or 0.0001, respectively.
Integrative analysis of the data Integrative analysis of DNA methylation and mRNA expression data were done by intersecting the most differentially methylated probes with the most differentially expressed genes on differentiation (Supplementary Table 2) . Genes, for which the associated CpG sites were among the most strongly differentially methylated on differentiation (DiffScore absolute value higher than 37) and for which the expression fold changes were higher than 1 as log-2 ratios, were considered as potentially regulated by DNA methylation of CpG sites in the regulatory region. For integrative analysis of miRNA data and mRNA data, target genes were predicted using TargetScan, Miranda and Pictar for the most significantly differentially expressed miRNAs (Supplementary  Table 3) . Targets predicted by all three algorithms with expression fold-changes higher than 1 (log-2 ratios) were considered as potentially regulated by miRNAs.
Cell culture conditions Glioblastoma samples were obtained from patients undergoing surgical resection according to the research proposals approved by the Institutional Review Board at the Medical Faculty, Heidelberg. Tissues were enzymatically dissociated and resuspended in stem cell medium (Dictus et al., 2007; Ernst et al., 2009 ; made of Dulbecco's modified Eagle medium/F-12 medium containing 20% BIT serum-free supplement, basic fibroblast growth factor and epidermal growth factor at a concentration of 20 ng/ml each (all Provitro, Berlin, Germany). Spheroids were cultured on uncoated tissue culture dishes (Sarstedt, Nu¨mbrecht, Germany). To induce differentiation, neurospheres were grown for 12 days in DMEM medium containing 10% fetal calf serum and 1 mM ATRA (Campos et al., submitted).
Nucleic acid isolation
Extraction of high molecular weight DNA and RNA from frozen tumor samples was performed via cesium chloride ultracentrifugation. Genomic DNA from blood of healthy donors and from cultured cells was isolated using the Blood and Cell Culture Kit (Qiagen, Hilden, Germany). The RNA from cultured cells was isolated using the RNeasy kit (Qiagen). Extraction of small RNAs was performed using the miRNeasy Kit (Qiagen). The RNA quality and concentration were assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
Luciferase reporter assay
To overexpress miR-18a, we cloned a 250-bp fragment of the gene containing the miR-18a sequence into a pCMX-PL1 vector (generous gift of Dr R Schu¨le, Department of Gynecology and Center for Clinical Research, Freiburg University, Medical School, Freiburg, Germany). The luciferase sensor construct was generated by cloning a 220-bp fragment from the CTGF 3 0 -untranslated region, containing the predicted miR-18a binding site, into a pMIR-REPORT vector (Ambion, Austin, TX, USA). Primer sequences are available in Supplementary Table 1 . The constructed pMIR-REPORT vector and an internal control (pRL-TK Renilla luciferase expression plasmid; Promega, Madison, WI, USA) were co-transfected with pCMX-miR-18a into NCH421k cells using TransIT transfection reagent (Mirus Bio, Madison, WI, USA). As a negative control, NCH421k cells were co-transfected with an empty pCMX vector. 24 h after transfection, the luciferase reporter assay was performed using a standard dual luciferase buffer system. The luminescence intensity of firefly luciferase was normalized to that of Renilla luciferase. Each sample was measured in triplicate and each assay was repeated four times.
Transfection of miRNA inhibitors Anti-miR miRNA inhibitors were purchased from Applied Biosystems. NCH421k glioblastoma spheroids, derived from a primary glioblastoma, were transfected with either 100 nM of anti-miR miRNA inhibitor or a negative control miRNA inhibitor using Hiperfect (Qiagen). Transfection efficiency was quantified by FACS analysis using FAM-labeled oligonucleotides as shown in Supplementary Figure 1 .
Cell proliferation assay
To assess the proliferation of GBIV spheroid cells in vitro, the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)-based CellTiter96 AQ Non-Radioactive Cell Proliferation Assay (Promega) was used following the manufacturer's recommendations. All samples were assayed in triplicate and experiments were performed in four biological replicas.
Cell viability assessment
Cell viability was determined using a Vi-CELL cell counter (Beckman Coulter, Fullerton, CA, USA) by trypan blue dye exclusion.
Apoptosis
Apoptotic cell death was detected by flow cytometry using Annexin V and 7-amino-actinomycin staining. Cells were collected and resuspended in Annexin V-binding buffer (10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)/ NaOH (pH 7.4), 140 mM NaCl and 2.5 mM CaCl 2 ) containing 10% Annexin V-phycoerythrin and 10% 7-amino-actinomycin staining solution (BD Biosciences, Heidelberg, Germany). After a 15-min incubation 4 1C, stained cells were analysed by flow cytometry using a FACSCanto flow cytometer equipped with the FACSDiva software (BD Biosciences, San Jose, CA, USA). Double-negative cells were counted as viable cells.
Western blot analysis
Cell lysates were separated through 10% SDS-PAGE and transferred to nitrocellulose membranes. All antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal mouse antibody against b-actin was used at a dilution of 1:5000, polyclonal rabbit antibody against phosphatase and tensin homolog at 1:500, monoclonal mouse antibody against E2F1 at 1:250, and monoclonal rabbit antibody against BCL2L11 at 1:500. Horseradish peroxidase-conjugated secondary antibodies (Abcam, Cambridge, UK) were used at a 1:5000 dilution before the chemiluminescent detection of protein (ECL kit; GE Healthcare, Little Chalfont, UK). The intensities of the bands were quantified using ImageJ software.
Array-based comparative genomic hybridization Array comparative genomic hybridization (matrix-CGH, Solinas-Toldo et al., 1997) was carried out as previously described (Mendrzyk et al., 2005 , Pfister et al., 2007 . Selection of genomic clones, isolation of bacterial artificial chromosome DNA, performance of degenerate oligonucleotide primed PCR, preparation of microarrays, labeling, hybridization, washing procedures and data analysis were performed as outlined elsewhere (Mendrzyk et al., 2005 , Pfister et al., 2007 . FISH Two-color interphase FISH (Lichter et al., 1990) was performed using a fluorescein isothiocyanate-labeled probe (RP11-282D2; miR-17-92) and a rhodamine-labeled 13q control probe. Pretreatment of slides, hybridization, post-hybridization processing and signal detection were performed as described previously. Samples showing sufficient FISH efficiency (490% nuclei with signals) were evaluated by two independent investigators. Signals were scored in, at least, 50 non-overlapping, intact nuclei. Metaphase FISH for verifying clone-mapping position was performed using peripheral blood cell cultures of healthy donors as outlined previously. Gains of 13q31.3 were defined by more than 5% of nuclei containing more than two additional signals of the probe for 13q31.3 compared with the control probe. Amplifications presented as innumerable tight clusters of signals for the probe for 13q31.3 (see, Figure 1 ).
FACS analysis of CD133 and glial fibrillary acidic protein expression See Supplementary Methods.
Pathway analysis
The canonical pathway analyses were generated through the Ingenuity Pathways Analysis (Ingenuity Systems, www.ingenuity.com). Genes that were more than two-fold differentially expressed between untreated and induced spheroid cultures and associated with a canonical pathway in the Ingenuity Pathways Knowledge Base were considered for the analysis.
Statistics
Paired t-tests were used to assess the significance of the difference in miRNA expression between untreated and induced cultures. Unpaired t-tests were used to assess the significance of the difference in cell viability, cell proliferation and mRNA expression level of targets between anti-miR-transfected cells and scrambled control-transfected cells. Unpaired t-tests were used to assess the significance of the difference in microRNA expression between normal brain and GBIV, as well as between astrocytoma grade II and secondary GBIV. Statistical significance was set at the level of Po0.05.
